Replacement in neuroscience

12.30 – 16.15 (GMT)/13.30 – 17.15 (CET)

Co-organised by the Swiss 3RCC and the French FC3R, this half-day online workshop will focus on human-based in vitro and in silico approaches to model and study the brain. Over two sessions talks will cover the development and application of replacement approaches to generate new insights into neurological processes and translate findings into therapeutic and safety applications.

Attendees are eligible for 0.5 day of accredited continuing education (for Swiss and French education systems).

Programme

Welcome

• Human pluripotent stem cells: A promising alternative to animal models in neuroscience.
  Dr Alexandra Benchoua, Centre d’Etude des Cellules Souches I-Stem, Université Evry Val d’Essonne.

Developing next-generation replacement methods to model and study the brain

• iPSC-derived human neurons and brain organoids development to study the pathophysiological impact of mutations identified in neuropsychiatric disorders.
  Dr Stéphane Jamain, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil.
• How engineering can help biologist to develop replacement models in neuroscience: Practical experience with companies.
  Dr Adrien Roux, Tissue Engineering Group, HEPIA HES-SO.
• Development of the Synapse Plasticity Tool for prediction of synapse plasticity outcome in silico.
  Dr Romain Veltz, INRIA National Institute for Research in Digital Science and Technology, Centre Côte d’Azur.

Translating human-based models into therapies and safety applications

• Landscape of paediatric high grade gliomas: Gaps and opportunities.
  Dr Javad Nazarian, DIPG/DMG Research Center, University Children’s Hospital Zurich.
• Modelling human neurodegeneration on a chip for ethical and successful drug development.
  Dr Maxime Cazorla, Institut de Neurosciences de La Timone, Université Aix-Marseille.
• Ex vivo study of the ADHD brain with iPSC-derived models: Prospects for pharmacological discoveries.
  Dr Edna Grünblatt, Department of Child and Adolescent Psychiatry, University of Zurich.
• Advancing neurotoxicity testing with human in vitro models: A human-based replacement approach.
  Dr David Pamies, Department of Biomedical Sciences, University of Lausanne.